Psyence Biomedical Ltd balance sheet PBMWW

Annual Quarterly

As of Mar 31, 2025, Psyence Biomedical Ltd had total assets of $7.3 million and total liabilities of $594,366. Total assets were up 546.2% from a year earlier. Stockholders' equity was $6.7 million. Cash and investments were $6.1 million.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Mar 31, 2025
FY 2024
Mar 31, 2024
Assets
Cash
6
+736.8%
1
Cash and investments
6
+736.8%
1
Total current assets
7
+482.3%
1
Property and equipment, net
0
+102.2%
0
Total assets
7
+546.2%
1
Liabilities and equity
Accounts payable
—
1
Total liabilities
1
-95.1%
12
Stockholders' equity
7
+161.3%
-11
Debt
Debt due within a year
—
10
Total debt
—
10
Net cash
—
-10
Ratios
Return on equity
15.05%
—
Return on assets
13.83%
-4,518.72%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PBM (Nasdaq), PBMWW (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Ontario, Canada
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1985062

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.